At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NxThera Benign Prostatic Hyperplasia Rezum System Pilot Study
In Brief
A clinical study evaluating Rezum System for Prostatic Hyperplasia and 7 related conditions. Completed, enrolled 50 participants across 3 sites in 3 countries.
Detailed Summary
Evaluate the safety and efficacy of the Rezum System for the treatment of BPH
Study Details
Timeline
Interventions
The Rezūm System treats patients with bothersome urinary symptoms associated with benign prostatic hyperplasia (BPH). The Rezūm System utilizes radiofrequency current to generate "wet" thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released, denaturing the cell membranes and causing cell death. The denatured cells are absorbed by the body, which reduces the volume of prostate tissue adjacent to the urethra. The vapor condensation process also causes a rapid collapse of vasculature in the treatment zone, resulting in a bloodless procedure.